Chk1 and Chk2 kinases in checkpoint control and cancer.

[1]  A. Gunasekera,et al.  Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents* , 2003, Journal of Biological Chemistry.

[2]  B. Vogelstein,et al.  The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells* , 2003, Journal of Biological Chemistry.

[3]  J. Bartek,et al.  Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent Phosphorylation of Chk1 on Ser-317 in Response to Ionizing Radiation* , 2003, The Journal of Biological Chemistry.

[4]  C. Stevens,et al.  Chk2 activates E2F-1 in response to DNA damage , 2003, Nature Cell Biology.

[5]  N. Perkins,et al.  DNA-dependent Acetylation of p53 by the Transcription Coactivator p300* , 2003, The Journal of Biological Chemistry.

[6]  Nazneen Rahman,et al.  Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. , 2003, American journal of human genetics.

[7]  Junjie Chen,et al.  p53 Binding Protein 53BP1 Is Required for DNA Damage Responses and Tumor Suppression in Mice , 2003, Molecular and Cellular Biology.

[8]  J. Bartek,et al.  Human Tousled like kinases are targeted by an ATM‐ and Chk1‐dependent DNA damage checkpoint , 2003, The EMBO journal.

[9]  J. Bartek,et al.  Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. , 2003, Cancer cell.

[10]  Y. Shiloh.  ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[11]  J. Bartek,et al.  Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage , 2003, Nature Cell Biology.

[12]  J. Bartek,et al.  MDC1 is required for the intra-S-phase DNA damage checkpoint , 2003, Nature.

[13]  Junjie Chen,et al.  MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways , 2003, Nature.

[14]  Stephen J. Elledge,et al.  MDC1 is a mediator of the mammalian DNA damage checkpoint , 2003, Nature.

[15]  Xiangao Sun,et al.  Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Zachos,et al.  Chk1‐deficient tumour cells are viable but exhibit multiple checkpoint and survival defects , 2003, The EMBO journal.

[17]  J. Herman,et al.  CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. , 2002, Blood.

[18]  Richard S. Paules,et al.  An ATR- and Chk1-Dependent S Checkpoint Inhibits Replicon Initiation following UVC-Induced DNA Damage , 2002, Molecular and Cellular Biology.

[19]  Jiri Bartek,et al.  53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer , 2002, Nature Cell Biology.

[20]  A. Nussenzweig,et al.  DNA damage-induced G2–M checkpoint activation by histone H2AX and 53BP1 , 2002, Nature Cell Biology.

[21]  R. Eeles,et al.  CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours , 2002, British Journal of Cancer.

[22]  Jiri Bartek,et al.  Regulation of G2/M events by Cdc25A through phosphorylation‐dependent modulation of its stability , 2002, The EMBO journal.

[23]  M. Smerdon,et al.  Rpb4 and Rpb9 mediate subpathways of transcription‐coupled DNA repair in Saccharomyces cerevisiae , 2002, The EMBO journal.

[24]  J. Bisi,et al.  PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2 , 2002, Nature Cell Biology.

[25]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[26]  Hui Zhao,et al.  Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Elledge,et al.  53BP1, a Mediator of the DNA Damage Checkpoint , 2002, Science.

[28]  R. Hollingsworth,et al.  Genotoxic Stress-Induced Activation of Plk3 is Partly Mediated by Chk2 , 2002, Cell cycle.

[29]  H. Dixon,et al.  Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 Function , 2002, Cell cycle.

[30]  E. Appella,et al.  Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription , 2002, The EMBO journal.

[31]  P. Jeggo,et al.  Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner , 2002, Molecular and Cellular Biology.

[32]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[33]  A. Millar,et al.  Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. , 2002, Cancer research.

[34]  T. Mak,et al.  Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Stern,et al.  Chk2 Activation and Phosphorylation-Dependent Oligomerization , 2002, Molecular and Cellular Biology.

[36]  C. McGowan,et al.  Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  C. Canman,et al.  Phosphorylation of Threonine 68 Promotes Oligomerization and Autophosphorylation of the Chk2 Protein Kinase via the Forkhead-associated Domain* , 2002, The Journal of Biological Chemistry.

[38]  L. Iyer,et al.  Determination of Substrate Motifs for Human Chk1 and hCds1/Chk2 by the Oriented Peptide Library Approach* , 2002, The Journal of Biological Chemistry.

[39]  Michael B Yaffe,et al.  Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. , 2002, Molecular cell.

[40]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[41]  S. Ogawa,et al.  Mutations of Chk2 in primary hematopoietic neoplasms. , 2002, Blood.

[42]  B. Gusterson,et al.  Analysis of CHK2 in vulval neoplasia , 2002, British Journal of Cancer.

[43]  J. Bartek,et al.  The DNA damage-dependent intra–S phase checkpoint is regulated by parallel pathways , 2002, Nature Genetics.

[44]  B. Gusterson,et al.  Concomitant inactivation of p53 and Chk2 in breast cancer , 2002, Oncogene.

[45]  Lawrence C. Brody,et al.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.

[46]  S. Elledge,et al.  Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. , 2002, Genes & development.

[47]  S. Elledge,et al.  Hus1 Acts Upstream of Chk1 in a Mammalian DNA Damage Response Pathway , 2002, Current Biology.

[48]  Carl W. Miller,et al.  Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors , 2002, Genes, chromosomes & cancer.

[49]  J. Bartek,et al.  Mammalian G1- and S-phase checkpoints in response to DNA damage. , 2001, Current opinion in cell biology.

[50]  J. Bartek,et al.  Chk2 kinase — a busy messenger , 2001, Nature Reviews Molecular Cell Biology.

[51]  Jun Qin,et al.  ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.

[52]  D. Sgroi,et al.  Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. , 2001, Cancer research.

[53]  S. Schwartz,et al.  Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. , 2001, Cancer research.

[54]  J. Bartek,et al.  Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours , 2001, Oncogene.

[55]  M. Protopopova,et al.  Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway , 2001, Oncogene.

[56]  C. Smythe,et al.  Activation of mammalian Chk1 during DNA replication arrest , 2001, The Journal of cell biology.

[57]  R. Abraham.  Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.

[58]  Jay H. Chung,et al.  The hCds1 (Chk2)-FHA Domain Is Essential for a Chain of Phosphorylation Events on hCds1 That Is Induced by Ionizing Radiation* , 2001, The Journal of Biological Chemistry.

[59]  L. Aaltonen,et al.  p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. , 2001, Cancer research.

[60]  S. Elledge,et al.  Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. , 2001, Cancer research.

[61]  N. Mailand,et al.  DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. , 2001, Cancer research.

[62]  R. Winqvist,et al.  Mutation analysis of the CHK2 gene in families with hereditary breast cancer , 2001, British Journal of Cancer.

[63]  H. Piwnica-Worms,et al.  ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1 , 2001, Molecular and Cellular Biology.

[64]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[65]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[66]  W. Hofmann,et al.  Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. , 2001, Leukemia research.

[67]  R. Barkardottir,et al.  Mutation analysis of the CHK2 gene in breast carcinoma and other cancers , 2001, Breast Cancer Research.

[68]  K. Khanna,et al.  DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.

[69]  Jing Chen,et al.  Characterization of Tumor-associated Chk2 Mutations* , 2001, The Journal of Biological Chemistry.

[70]  Carl W. Miller,et al.  Analysis of the CHK2 Gene in Lymphoid Malignancies , 2001, Leukemia & lymphoma.

[71]  M. Kastan,et al.  The many substrates and functions of ATM , 2000, Nature Reviews Molecular Cell Biology.

[72]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[73]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[74]  A. Kumagai,et al.  Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. , 2000, Molecular cell.

[75]  H. Konishi,et al.  Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. , 2000, Cancer research.

[76]  Y. A. Minamishima,et al.  Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. , 2000, Genes & development.

[77]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[78]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[79]  S. Elledge,et al.  BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. , 2000, Genes & development.

[80]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[81]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[82]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[83]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[84]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[85]  E. Stavridi,et al.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[86]  M. Broggini,et al.  CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers , 1999 .

[87]  M. Nakanishi,et al.  Cell cycle-dependent and ATM-independent expression of human Chk1 kinase , 1999, Oncogene.

[88]  Yue Li,et al.  NMR Solution Structure of Domain 1 of Human Annexin I Shows an Autonomous Folding Unit* , 1999, The Journal of Biological Chemistry.